Background
Toray Industries holds a Japanese patent claiming the use of nalfurafine hydrochloride for treating pruritus (itching). The patent received an extension of term registration (存続期間の延長登録) tied to the regulatory approval of Toray’s branded product Remitch®, an oral capsule used to treat itching in dialysis patients and patients with chronic liver disease. Sawai Pharmaceutical and a second generic launched competing nalfurafine hydrochloride products before the extended term expired. Toray sued for patent infringement and damages.
The Tokyo District Court (東京地裁) initially ruled for the generic manufacturers, finding that the extended patent’s scope did not reach the generics. Toray appealed to the IP High Court’s Second Division. The case was decided by Presiding Judge SHIMIZU Hibiki, who at the time of decision was considered the leading IP-bench voice on Japanese pharmaceutical patent extension scope.
The Court’s Holding
The IP High Court reversed the Tokyo District Court and entered a partial judgment for Toray, awarding approximately ¥21.7 billion in damages. The decision elaborates three legal points that materially expand the practical scope of Japanese pharmaceutical patent extension rights.
(1) “Active ingredient” identity (有効成分の意義). The Court held that for purposes of analyzing the scope of an extended patent’s effect, the relevant “active ingredient” includes salt forms and formulations that release the claimed compound in vivo. A generic product whose nominal API is a different salt form — but which delivers the same active moiety to the patient — is treated as embodying the same active ingredient. This rejects a narrow, formalist reading of active-ingredient identity that would let generics evade extension scope through trivial salt-form switches.
(2) Extended patent scope is functional, not formal (実質的同一性). The extended patent right reaches drugs whose composition, dosage, administration route, and clinical indication are substantively identical (実質的に同一) to the regulatory-approved branded product. Strict formal identity is not required; the test is whether the generic product is the substantive functional equivalent of the branded product on the dimensions that matter to the regulatory approval that supported the extension.
(3) Restoration period stacking (回復期間の通算). The Court ruled that prior clinical trial periods for different dosage forms or indications of the same active ingredient may be counted toward the restoration-period calculation that supports a later extension application. This is favorable to originators who develop a single API across multiple dosage forms and clinical indications and apply for term extensions in stages.
On damages, the Court adopted Toray’s lost-profits calculation methodology and entered an award of approximately ¥21.7 billion (approximately US$140 million). The damages number reflects substantial generic uptake during the alleged-infringement window.
Key Takeaways
- Japanese extended pharmaceutical patents now reach generic launches that share the same active moiety, even where the nominal salt form differs. Salt-form switching alone is no longer a viable design-around for generics during a patent’s extended term.
- The substantive-identity test for extended-patent scope means generics must differ on a dimension that materially distinguishes the regulatory profile — not just on chemistry that releases the same in-vivo agent.
- Restoration-period stacking favors originators with multi-product franchises built on a single API. Companion or follow-on dosage forms can benefit from earlier clinical-trial periods.
- The damages number — approximately ¥21.7 billion — is exceptionally large for Japanese patent litigation and signals that the IP High Court is increasingly comfortable with substantial damages awards in pharmaceutical cases when the patentee establishes a credible lost-profits theory.
- Generic-manufacturer defendants will face more challenging timing decisions: launching at-risk against a Japanese extended pharmaceutical patent now carries materially higher exposure than under the prior Tokyo-District-level reading of § 68-2.
Why It Matters
Japanese pharmaceutical patent extension scope has been a contested doctrinal area for at least a decade, with various Tokyo District panels reaching inconsistent results on whether extended-term protection covers generics with non-identical formulations or salt forms. The IP High Court Second Division’s 2025 Remitch ruling provides the clearest appellate guidance to date and decisively shifts the balance toward originators. Brand-name pharmaceutical companies operating in Japan now have substantially stronger extension-scope rights, and generic manufacturers must rethink launch timing and product-design strategies for compounds whose originator has obtained term extensions.
The decision also affects deal-making and regulatory strategy. Multi-indication, multi-dosage-form pharmaceutical franchises in Japan are now more valuable because the restoration-period stacking rule extends effective patent life across the franchise. License negotiations and brand-acquisition transactions involving Japanese patent extensions should be revalued in light of this ruling.
Open questions remain — notably whether the Japanese Supreme Court will accept the appeal that defendants have signaled, and how the IP High Court’s substantive-identity test will be applied to non-pharmaceutical regulatory-approved products (medical devices, agrochemicals) that also use Japan’s extension-of-term system. For now, however, Japanese pharmaceutical patentees have a materially stronger enforcement tool.